Biocon advanced 1.34% to Rs 392.25 after the company said that Biocon Biologics (BBL) has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in Australia.

Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid ...

The shares of biopharmaceutical firm Biocon fell as much as 2.04 per cent in Tuesday's trading session, figuring among top ...

Shares of Biocon experienced a decline of 2.01% to Rs 386.70 in Tuesday's session, with the stock figuring among the top ...

Biocon Biologics (BBL), a fully integrated global biosimilars company and subsidiary of Biocon, announced today it has launched Nepexto(R), a biosimilar to the reference ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

When Indian biotechnology firm Biocon and the world's biggest pharma company Pfizer announced their $350-million alliance in late October, the industry took it as another biotech pharma deal--by ...

RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

The stock’s current performance reflects a positive investor response, with Biocon demonstrating promising financial results and engaging in active corporate actions.

Biocon and Viatris expect to close the transaction in the second half of this year. When it happens, Viatris will have one nominee on the Biocon board of directors.

Indian biopharmaceutical company Biocon Ltd is planning to list its biosimilars business, a significant contributor to the company's total revenue, by the first half of 2025, a top executive said ...